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Objective: Anthracyclines are successfully used in
cancer treatment, but their use is limited by their
cardiotoxic side effects. Several risk factors for
anthracycline-associated cardiomyopathy (AACM) are
known, yet the occurrence of AACM in the absence of
these known risk factors suggests that other factors
must play a role. The purpose of this study was to
evaluate whether a genetic predisposition for dilated
cardiomyopathy (DCM) could be a potential risk factor
for AACM.
Methods: A hospital-based registry of 162 DCM
families and two hospital-based registries of patients
with cancer treated with systemic cancer therapy
(n>6000) were reviewed focusing on AACM. Selected
patients with AACM/DCM families with possible AACM
(n=21) were analysed for mutations in cardiomyopathy-
associated genes and presymptomatic cardiological
evaluation of first-degree relatives was performed.
Results: We identified five DCM families with AACM
and one patient with AACM with a family member with
a possible early sign of mild DCM. Pathogenic MYH7
mutations were identified in two of these six families.
The MYH7 c.1633G>A (p.Asp545Asn) and c.2863G>A
(p.Asp955Asn) mutations (one double mutant allele)
were identified in a DCM family with AACM. The MYH7
c.4125T>A (p.Tyr1375X) mutation was identified in
one patient with AACM.
Conclusions: This study further extends the
hypothesis that a genetic predisposition to DCM could
be a potential risk factor for AACM.
INTRODUCTION
Anthracyclines, such as doxorubicin, epirubi-
cin and daunorubicin, are important drugs
in the treatment of cancer. Their use in clin-
ical practice is hampered by their cardiotoxic
side effects.1–3 These effects are variable and
range from transient electrophysiological
abnormalities to anthracycline-associated car-
diomyopathy (AACM) and heart failure.1–4
AACM typically presents as left ventricular
(LV) dysfunction/dilated cardiomyopathy
(DCM) in adults. In children, AACM may
also present as restrictive cardiomyopathy.4 5
AACM may become apparent during anthra-
cycline therapy, or within the ﬁrst year there-
after, or later (sometimes even 10–20 years
KEY MESSAGES
What is already known about this subject?
▸ Anthracyclines can cause anthracycline-associated
cardiomyopathy (AACM). Several risk factors for
AACM are known. However, other risk factors
must exist as AACM also occurs in the absence
of these risk factors.
How might this impact on clinical practice?
▸ The results of our study provide further support
for the hypothesis that a genetic predisposition
for familial dilated cardiomyopathy (DCM) could
be a potential risk factor for anthracycline-
cassociated cardiomyopathy (AACM). Although
more research is needed, our preliminary results
should alert clinicians to the possibility of AACM
if a patient reports a personal and/or familial
history of DCM/heart failure. Conversely, if a
patient with cancer develops disproportional LV
dysfunction after anthracycline treatment, one
could consider offering the index patient DNA
analysis of cardiomyopathy-associated genes and
presymptomatic cardiological evaluation to first-
degree family members.
What does this study add?
▸ In patients with cancer with a family history of
dilated cardiomyopathy (DCM)/heart failure, one
should be vigilant for increased susceptibility to
anthracycline-associated cardiomyopathy (AACM)
and one may consider more intensive cardiovas-
cular monitoring before and during cancer treat-
ment or alternative non-cardiotoxic cancer
therapy.
▸ Identifying a cardiomyopathy-related mutation
facilitates genetic cascade screening in family
members, which can be helpful in identifying
individuals at risk (and in dismissing relatives
who do not carry the mutation from regular
cardiac monitoring). This enables timely diagno-
sis to be made, with the possibility of preventing
complications and reducing morbidity and
mortality.
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after treatment).4 6 It has been suggested that anthracy-
clines cause cardiac dysfunction through myocyte
damage due to excess production of reactive oxygen
species.7 8 However, other mechanisms, such as
anthracycline-dependent inhibition of topoisomerase II
β and selective inhibition of cardiomyocyte-speciﬁc gene
expression, have also been proposed.7 9 The risk of
AACM depends on the cumulative dose of administered
anthracyclines.1 2 In adults, the recommended
maximum cumulative doses of doxorubicin and epirubi-
cin are (in general) 550 and 900 mg/m2, respectively.10
In children, the maximum cumulative dose of anthracy-
clines is (in general) 450 mg/m2.11 Additional risk
factors for AACM have been identiﬁed, including both a
younger age as well as an older age at treatment, female
gender, mediastinal radiation and pre-existing heart
disease.1 2 12 Yet, the occurrence of AACM in the
absence of these known risk factors suggests that other
predisposing factors must play a role.
Recently, we reported two patients with AACM with
multiple family members diagnosed with DCM, suggest-
ing the presence of a genetic predisposition for DCM in
these families.13 In one of these families, we conﬁrmed
this ﬁnding by identifying a double mutant MYH7 allele.
Based on these observations we hypothesise that a
genetic/familial predisposition for DCM might be a
potential risk factor for AACM.
To further corroborate the concept that a genetic/
familial predisposition for DCM might be a potential
risk factor for AACM, we have searched for patients with
AACM in our registry of DCM families and, reciprocally,
searched for the presence of familial cardiomyopathy in
patients with AACM among two registries of patients
with cancer treated with systemic therapy.
METHODS
Patients and clinical evaluation
Patients with AACM were selected from our hospital-
based registry of proven DCM families (cohort I14) and
from two hospital-based registries of patients with cancer
(adult or childhood onset) treated with systemic therapy
(cohort II—adult onset patients, cohort III—childhood
onset patients15). For the ﬂow chart of patient inclusion,
see ﬁgure 1. All participants seen at our cardiogenetics
outpatient clinic underwent a counselling procedure
and agreed to take part in our study. The institutional
review committee approved the protocol.
Cohort I: Hospital-based registry of DCM families
Patients with idiopathic DCM (and other putative inher-
ited cardiac disorders) are routinely evaluated at the car-
diogenetics outpatient clinic of the University Medical
Center Groningen, including registration of the patients’
clinical and family history, construction of pedigrees and
if indicated DNA analysis. Family members at risk are
invited for presymptomatic cardiac screening and/or, in
those families where a mutation is identiﬁed,
presymptomatic DNA analysis. To inform family
members at risk, the index patients are asked to distrib-
ute letters to their family.16 DCM is diagnosed using the
generally accepted criteria by Mestroni et al, that is,
reduced systolic function (left ventricular ejection frac-
tion (LVEF) <0.45) and dilation of the left ventricle (LV
end-diastolic dimension >117% of the predicted value
corrected for body surface area and age) without identi-
ﬁable causes such as severe hypertension, coronary
artery disease and systemic disease.17 Mild DCM is diag-
nosed if only one of these criteria is fulﬁlled. Familial
DCM is deﬁned by at least two family members with
(mild) DCM or by a patient with DCM with a ﬁrst-degree
relative who died suddenly before the age of 35 years.
We reviewed all familial DCM index patients (n=162)
and their family members registered at the cardioge-
netics outpatient clinic as of 1 January 2012 for the pres-
ence of AACM. AACM was deﬁned by patients who
developed DCM (without coronary artery disease or
other identiﬁable causes) after treatment with cumula-
tive doses of doxorubicin ≤450 mg/m2 and cumulative
doses of epirubicin ≤600 mg/m2 (with or without add-
itional trastuzumab therapy). By using cut-off values that
are lower than the generally accepted safety margins of
<550 mg/m2 for doxorubicin and <900 mg/m2 for epir-
ubicin,10 we aimed to include patients who received at
most a submaximal dose of anthracyclines.
Cohort II: Hospital-based registry of adult-onset patients
with cancer treated with systemic cancer therapy
Since the late 1980s, the Department of Medical
Oncology of the University Medical Center Groningen
has routinely collected clinical data on patients with
cancer who have been treated with systemic therapy at
the University Medical Center Groningen. In this regis-
try, we reviewed all patients (n=6107) for the presence of
AACM. AACM was deﬁned by patients diagnosed with a
reduced systolic function (LVEF <0.50) after anthracy-
cline treatment, according to the aforementioned cut-off
values and after excluding other identiﬁable causes for
LV dysfunction. All patients with AACM who were alive,
with no evidence of active malignant disease and with a
follow-up of at least 3 years, were informed about the
study and asked to complete a questionnaire about their
family medical history. Selected patients with AACM who
agreed to participate in the study were counselled at our
cardiogenetics outpatient clinic (see ﬁgure 1 for inclu-
sion criteria). A family history suggestive of DCM was
assigned if patients reported one or more relatives with
possible heart failure, cardiomyopathy, pacemaker/
implantable cardioverter deﬁbrillator (ICD) therapy
and/or sudden cardiac death before the age of 60 years
(excluding relatives with identiﬁable causes for cardiac
disease or sudden death, such as coronary artery
disease).
Patients with an LVEF <0.30 at follow-up, or with a per-
sistent LVEF ≤0.45 and a ﬁrst-degree relative with
possible cardiomyopathy or myopathy, were offered next
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generation DNA sequencing targeting 48 cardiomyopathy-
associated genes and cardiological examination of
ﬁrst-degree family members. All other patients were
offered limited DNA analysis of four DCM-related genes.
Cohort III: Hospital-based registry of childhood-onset
patients with cancer treated with systemic cancer therapy
Between 1976 and 1999, the Division of Pediatric
Oncology, Beatrix Children’s Hospital, University
Medical Center Groningen has collected the clinical
data of childhood-onset patients with cancer treated
with systemic cancer therapy who survived at least 5 years
after diagnosis. As part of a research project on late
effects on cardiovascular damage and risk factors,
cardiac examinations (including echocardiography)
were performed on 277 patients.15 Using this cohort of
277 patients, we searched for patients with AACM who
were treated with a total cumulative dose of doxorubin
≤450 mg/m2 and had (1) a wall motion score index
(WMSI) ≥1.5 and a shortening fraction (SF) <0.29, or
(2) a WMSI ≥1.5 or an SF <0.29 and a family history sug-
gestive for DCM. All included patients had, apart from
their treatment, no other identiﬁable causes for LV dys-
function. Patients who showed recovery of LV function
without therapy during follow-up (LVEF >0.55) were
excluded. A family history suggestive of DCM was
assigned according to the aforementioned criteria (see
cohort II). Patients eligible for our study were coun-
selled at our cardiogenetics outpatient clinic and, upon
patients’ consent, next-generation DNA sequencing tar-
geting 48 cardiomyopathy-associated genes was
performed.
Genetic analysis
Blood-derived genomic DNA was obtained from all
index patients of DCM families with apatient with AACM
(cohort I) and the selected patients with AACM from
cohorts II and III. All index patients included in cohort
I, cohort III, and all patients with an LVEF <0.30 at
follow-up or with a persistent LVEF ≤0.45 and a ﬁrst-
degree relative with possible cardiomyopathy or myop-
athy from cohort II were screened for mutations in 48
cardiomyopathy-associated genes (ABCC9, ACTC1,
ACTN2, ANKRD1, BAG3, CALR3, CRYAB, CSRP3/MLP,
DES, DMD, DSC2, DSG2, DSP, EMD, GLA, JPH2, JUP,
LAMA4, LAMP2, LMNA, MYBPC3, MYH6, MYH7, MYL2,
MYL3, MYPN, MYOZ1, MYOZ2, PKP2, PLN, PRKAG2,
PSEN1, PSEN2, RBM20, RYR2, SCN5A, SGCD, TAZ,
Figure 1 Flow chart patient inclusion. Patients with AACM data were collected from the hospital-based registry of DCM families
(cohort I) and two hospital-based registries of patients with cancer (adult- or childhood-onset) treated with systemic cancer
therapy (cohort II-adult-onset patients and cohort III-childhood-onset patients). AACM, anthracycline-associated cardiomyopathy;
DCM, dilated cardiomyopathy; FU, follow-up; LVEF, left ventricular ejection fraction; SF, shortening fraction; WMSI, wall motion
score index.* Two patients from a previously published study.13 †Using the cut-off values of ≤450 mg/m2 for doxorubicin and
≤600 mg/m2 for epirubicin, we aimed to include patients who received at most the submaximal dose of anthracyclines.
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TBX20, TCAP, TMEM4, TNNC1, TNNI3, TNNT2, TPM1,
TTN, VCL and ZASP/LDB3) using targeted next-
generation DNA sequencing.18 All novel variations were
conﬁrmed by Sanger sequencing. In the remaining
index patients from cohort II (n=10), we only analysed
the complete coding sequence and intron/exon bound-
aries of four DCM-related genes (PLN, MYH7, LMNA
and TNNT2) with Sanger sequencing.19 Details of these
analyses are available on request. Classiﬁcation of the
variants identiﬁed was performed according to criteria
previously published in van Spaendonck-Zwarts et al.19
Variants were classiﬁed as not pathogenic, variant of
unknown clinical signiﬁcance (VUS; VUS1, unlikely to
be pathogenic; VUS2, uncertain; VUS3, likely to be
pathogenic), or (putative) pathogenic. Co-segregation
analysis of VUSs and mutations was performed where
possible.
RESULTS
Patient selection and cardiological evaluation
Cohort I: Hospital-based registry of DCM families
Among our hospital-based registry of 162 DCM families,
we identiﬁed ﬁve DCM families with at least one patient
with AACM (ﬁgure 1). Two of the ﬁve families (Id and
Ie) had also been identiﬁed in the childhood cancer
registry (cohort III) and were previously published.13 In
families Ia and Ib, we identiﬁed one patient with AACM
and two family members with (mild) DCM. In family Ic,
we identiﬁed three sisters, two of whom had AACM and
one DCM. A fourth sister had died suddenly at the age
of 62 years. In family Id, we identiﬁed two ﬁrst-degree
relatives (father and brother) of the patient with AACM
with (mild) DCM. In family Ie, three relatives (father,
brother and paternal uncle) of the patient with AACM
had (mild) DCM (table 1 and ﬁgure 2).
Cohort II: Hospital-based registry of adult-onset patients
with cancer treated with systemic cancer therapy
After applying our selection criteria (ﬁgure 1), 43
patients were informed about our study and asked to ﬁll
out a questionnaire including questions about family
history. Thirteen of these patients were eligible for our
study (table 1 (patients IIa through IIn)).
Presymptomatic cardiological screening of ﬁrst-degree
relatives was offered to 3/13 patients: patients IIk, IIm,
IIn (table 1). Three daughters of the index patient in
family IIk underwent cardiological examination. Two
showed no signs of DCM, while one was diagnosed with
subnormal LV function (LVEF 0.50). Analysis of the
pedigree showed that the brother of patient IIk was diag-
nosed with a dilated LV with preserved function and
atrial ﬁbrillation (AF) (see ﬁgure 2). Family members of
patient IIm did not respond to our invitation. In family
IIn, cardiological examination of a son of patient IIn
showed no signs of DCM although this patient did have
a left bundle branch block, which can be considered a
possible precursor of DCM (see ﬁgure 2).
Cohort III: Hospital-based registry of childhood-onset
patients with cancer treated with systemic cancer therapy
Six patients with AACM of the childhood cancer registry
met our selection criteria (ﬁgure 1). Of these, one
declined to participate and two other patients were
already included in cohort I (patients Id and Ie). In
family IIIa, we identiﬁed a second-degree relative of the
index patient who died suddenly at the age of 56 years.
In family IIIb, we identiﬁed a second-degree relative
diagnosed with AF and heart failure. In family IIIc, the
father of the index patient was diagnosed with arrhyth-
mia (unspeciﬁed) and a cousin of the mother of the
index patient had died unexpectedly at the age of
40 years. Detailed clinical data and relevant family data
of patients IIIa, IIIb, IIIc are shown in table 1.
Genetic analysis
The genomic DNA of all index patients in DCM families
with patients with AACM (cohort I, n=5) and six patients
with AACM (n=3 from cohort II and n=3 from cohort
III) were screened for mutations in 48
cardiomyopathy-associated genes using next-generation
DNA sequencing.18 Two pathogenic mutations, six
VUS1s, and three VUS2s were identiﬁed (table 2).
The two pathogenic mutations included a previously
reported complex mutation (two missense mutations in
MYH7 on one allele, c.1633G>A (p.Asp545Asn) and
c.2863G>A (p.Asp955Asn)) in family Ie13 20 and a non-
sense mutation (c.4125T>A (p.Tyr1375*) in MYH7) in
family IIn. Co-segregation analysis showed that the
complex mutation fully segregated with disease in family
Ie.13 Co-segregation analysis of the nonsense mutation
could not be performed, as there was no DNA available
from the possibly affected son of the index patient
(family IIn). Sanger sequencing for mutations in the
PLN, MYH7, LMNA and TNNT2 genes in the remaining
patients of cohort II (n=10) revealed one VUS2 in
family IIc (MYH7 c.5534G>A, p.Arg1845Gln).
DISCUSSION
This study is the ﬁrst to systematically investigate the
concept that a genetic/familial predisposition for DCM
might be a potential risk factor for AACM. In addition
to the patients identiﬁed in our initial report,13 we have
identiﬁed three new DCM families with patients with
AACM (families Ia, Ib and Ic) and revealed previously
undiagnosed precursor signs of mild DCM in a ﬁrst-
degree relative of a patient with AACM (family IIn).
Moreover, in two families (Ie and IIn), we identiﬁed
pathogenic MYH7 mutations. These two pathogenic
MYH7 mutations highlight the genetic nature of familial
DCM in these families. Yet, this does not prove a causal
relation between the identiﬁed MYH7 mutations and
the development of AACM in these families, as AACM
developed years after anthracycline treatment and other
(non-genetic) risk factors might have been involved in
AACM development.
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Gy (location) 1st DGRs 2nd DGRs ≥3rd DGRs
Cohort I (n=5)







Ib B (55) 240† <1 month 0.41 0.40, after
1 year
CACS: 0 DCM (59) mild DCM
(33)
Ic B (49) 450† 168 0.34 unknown CAG normal DCM+CABG
(57)
B (57) unknown† unknown 43 unknown 0.42, after
7 months
LBBB SCD (62)



















IIa B (58) 455* 3 0.36 0.45, after
5 year
arrhythmia





IIc B (47) 332* 46 (L) 21 0.44 0.50–0.55,
after 13 year
HF (70) SCD (40) SCD (32)






















IIi B (44) 309† 50 (L) 126 0.46 0.50, after
4 year










































































Gy (location) 1st DGRs 2nd DGRs ≥3rd DGRs
IIm B (45) 190† 58 (R) 122 0.45 0.23, after
16 year
ICD, LBBB
IIn B (61) 450* 64 (L) 30 0.40 0.40–0.45,
after 5 year
CAG normal MP (<15),
LBBB (43)
Cohort III (n=3)









IIIc W (4, 7) 240† 123 0.27§ 0.40–0.45,
after 19 year
arrhythmia SCD (40)
Patients Ia, Ib, Ic, Id, Ie and IIn (indicated in bold) are patients with AACM and familial DCM and/or pathogenic mutation.
AACM, anthracycline-associated cardiomyopathy; AC, anthracyclines; AF, atrial fibrillation; ALL, acute lymphoid leukaemia; B, breast cancer; BB, bilateral breast cancer; CABG, coronary artery
bypass graft; CAG, coronary angiography; CACS, coronary artery score; CM, cardiomyopathy; CRT, cardiac resynchronisation therapy; CVA, cerebrovascular accident; DCM, dilated
cardiomyopathy; DGRs, degree relative; dil., dilated; E, extremities; HF, heart failure; Gy, gray; ICD, implantable cardioverter defibrillator; L, left thorax; LBBB, left bundle branch block; LV, left
ventricle; LVEF, left ventricular ejection fraction; MP, myopathy; MR, mitral regurgitation; N, neuroblastoma; PM, pacemaker; PNET, primary neuroectodermal tumour; Pt, patient; R, right thorax;



































In the literature, we found two other reports of
patients with AACM with a positive family history of car-
diomyopathy.21 22 Interestingly, one of these families also
carried a MYH7 mutation (MYH7 c.4276G>A, p.
Glu1426Lys). Hence, thus far, MYH7 mutations have
been described in three of eight patients with AACM.
Based on these numbers, one might speculate that
MYH7 mutations are more frequent in families with
DCM and AACM compared with lone DCM families.19
However, this ﬁnding is likely to be coincidental and
also does not, as indicated before, prove a causal relation
between the development of AACM and MYH7 mutation
carriership. Given the large heterogeneity of DCM, it is
plausible that genetic analysis of larger numbers of
patients with AACM will probably reveal pathogenic
mutations in cardiomyopathy-associated genes other
than MYH7.
In addition to pathogenic MYH7 mutations, we identi-
ﬁed several variants of unknown clinical signiﬁcance
(VUS1s and VUS2s). Based on current knowledge, it is
not clear whether these variants are involved in the
pathogenesis of DCM. It is possible that they represent
only benign sequence variations. However, it is conceiv-
able that these variants are low-risk or high-risk patho-
genic alleles or modiﬁers. This is especially the case for
the VUS2 reported in VCL (c.2969C>T, p.Ala990Val) in
family Ic. This variant has not been reported before in
cardiomyopathy patients or in the 1000 Genomes
project. It has been reported at low frequencies in
∼6500 exomes of the exome sequencing project (ESP)
of the National Heart, Lung, and Blood Institute
(NHLBI) (minor allele frequency (MAF) 0,0003) and
1000 Dutch genomes of the GoNL project (MAF 0,003).
In addition, the Ala990 amino acid position is highly
conserved and several prediction programs classify this
amino acid substitution as pathogenic. Moreover, segre-
gation analysis showed that this variant fully segregated
with the disease in this family.
Our results support the hypothesis that a genetic/
familial predisposition for DCM might be a potential
Figure 2 Pedigrees of patients with AACM and their family members. Square symbols, men; circles, women; diamonds,
unknown sex. Blue symbols, patients with AACM; solid black symbols, patients with (mild) DCM; grey symbols, possible DCM;
orange symbols, sudden cardiac death. Diagonal lines through symbols, deceased; arrow, index patient; number in a symbol,
number of individuals with this symbol.
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risk factor for AACM. The question remains: what is the
potential mechanism? A conceivable mechanism could
be that genetic inactivation of DCM associated proteins
may lower the threshold for the damaging effect of
anthracyclines on cardiomyocytes and cardiac func-
tion.23 Depending on reserve and restoration capacity
this may result in AACM at a lower threshold.24
Limitations and future research
The descriptive nature of our study design did not
enable us to perform statistics on our hypothesis that a
genetic predisposition for DCM might be a potential
AACM risk factor. Nor did it allow to statistically address
the several confounders leading to AACM (such as
radiotherapy or coronary artery disease). Also, given that
cancer and heart disease are both common diseases of
the ageing population,25 it is possible that some
included patients developed heart failure independently
of anthracycline treatment.26 On the other hand, cardio-
logical evaluation and cardiac follow-up were not offered
to all patients treated with anthracyclines. Since signs of
AACM may only become clinically evident several years
after anthracycline treatment,4 6 it is plausible that we
have underestimated the true number of patients with
AACM in our study. Further, it is conceivable that some
of the patients are carriers of currently unknown patho-
genic mutations because, at present, a genetic cause can
be found in only ∼50% of patients with DCM.19 27
More research is needed to further elucidate the intri-
guing relationship between a potential genetic predispos-
ition for DCM and AACM. Ideally, this should be
multicentre systematic studies including next generation
DNA analysis (gene panel-based and/or exome sequen-
cing) in patients with AACM, and cardiological screening
of ﬁrst-degree family members. Not only will such studies
add to our understanding of the aetiology of AACM and
lead to the identiﬁcation of patients at a high risk for
AACM, they may also lead to the identiﬁcation of novel
targets important for the prevention of AACM or even
novel cardiomyopathy susceptibility genes.
Conclusion
We have identiﬁed ﬁve DCM families with one patient
with AACM, and one patient with AACM with a family
member with a previously unrecognised, possible early
sign of mild DCM. In two of these families, we identiﬁed
pathogenic MYH7 mutations, conﬁrming the genetic
character of the DCM in these families. Although more
research is needed, our current data support the hypoth-
esis that a genetic susceptibility for DCM is a potential
risk factor for AACM. In view of the reported cases, one
should be vigilant for increased susceptibility to AACM if
patients report a family history of DCM/heart failure
and one may, in these particular cases, consider more
intensive cardiovascular monitoring before and during
cancer treatment or alternative non-cardiotoxic cancer
therapy.
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Table 2 Sequence variants identified through next-generation DNA sequencing of 48 cardiomyopathy-associated genes
Patient Gene† Nucleotide change Predicted protein change Type of variant
Cohort I
Ia DSG2 c.473T>G p.Val158Gly VUS1
Ib JUP c.1942G>A‡ p.Val648Ile VUS1
Ic VCL c.2969C>T‡ p.Ala990Val VUS2
Id −§ – – –
Ie MYH7 c.1633G>A+c.2863G>A‡ p.Asp545Asn+p.Asp955Asn Pathogenic
TTN c.94036_94037delinsCT p.Ser31346Leu VUS1
TTN c.13358A>G‡ p.Tyr4453Cys VUS2
Cohort II
IIk −§ – – –
IIm DSP c.4274G>A p.Arg1425Lys VUS1
IIn MYH7 c.4125T>A p.Tyr1375* Pathogenic
Cohort III
IIIa ABCC9 c.2215G>C p.Pro739Ala VUS1
IIIb PKP2 c.1592T>G p.Ile531Ser VUS2
TTN c.32562_32564dupAGA p.Glu10855dup VUS1
IIIc −‡ – – –
VUS indicates variant of unknown clinical significance (VUS1, unlikely to be pathogenic; VUS2, uncertain).
†Nomenclature according to HGVS (Human Genome Variation Society) using the reference sequences: ABCC9 (NM_005691.2), DSG2
(NM_001943.3), DSP (NM_004415.2), JUP (NM_002230.2), MYH7 (NM_000257.2), PKP2 (NM_004572.3), TTN (NM_001256850.1;
Q8WZ42), and VCL (NM_014000.2).
‡Co-segregation analysis revealed carriership in all the affected family members.
§No variations identified among 48 cardiomyopathy-associated genes.
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